医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NantHealth® Advances Clinician Productivity and Critical Patient Information Access with Enhancements to DeviceConX™

2018年11月08日 AM04:24
このエントリーをはてなブックマークに追加


 

BRISBANE, Australia & CULVER CITY, Calif.

NantHealth (NASDAQ: NH), a leader in breakthrough cancer research and data solutions that improve patient care and lower healthcare costs, today announced updates to its Connected Care portfolio of medical device integration (MDI) products, including DeviceConX, VitalsConX, HBox®, and Shuttle. NantHealth’s Connected Care solutions integrate medical device data into clinical records which may lead to reduced length of stay, less costly medical errors, greater provider satisfaction and improved care.

An extremely flexible software-based solution, DeviceConX facilitates the capture of patient data from any capable medical device. Leveraging a combination of existing hardware investments—including bedside PCs, laptops, tablets, workstations-on-wheels, and NantHealth’s HBox hardware—DeviceConX then delivers that data to an EMR or any other clinical system quickly and accurately.

DeviceConX version 5.15 will include the ability to:

  • Support high-resolution, high-fidelity medical device data, including waveform capture
  • Push over-the-air (OTA) client upgrades and security patches to HBox devices
  • Deliver enterprise functionality for larger health systems, including support for networks that exist across time zones, role-based access limitations for larger support teams, and remote management of NantHealth HBox devices from the DeviceConX console

Additionally, NantHealth is proud to announce the NantHealth Shuttle, a medical-grade RS-232 DB9 serial-to-USB interface cable that will soon be released to replace the previous version called the Device Escort. This cable is used to stream serial proprietary data to a node (either an HBox or a Windows® PC running DeviceConX Client). The new NantHealth Shuttle will include the following features:

  • IEC 60601-1 and 61000-4-2-compliance to ensure reliability
  • Medical grade, IP52-rated construction for superior durability for any medical environment
  • Superior interface featuring multi-color activity and connection LEDs for a better user experience

NantHealth showcased DeviceConX, HBox, and NantHealth Shuttle as part of the HIMSS Interoperability Showcase AsiaPac ‘18, held on Nov. 5-8 at the Brisbane Convention & Exhibition Centre in Brisbane, Australia. For more information, visit NantHealth at booth #307 or at https://info.nanthealth.com/himssapac-2018.

About NantHealth, Inc.

NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth’s focused portfolio exemplifies its unique systems-based approach to personalized healthcare and integrates novel diagnostics with large-scale, biometric and phenotypic data to track patient outcomes and deliver precision medicine. For more information, please visit www.nanthealth.com.

About HIMSS

HIMSS is a global advisor and thought leading organization supporting the transformation of health through the application of information and technology. As a mission driven non-profit, HIMSS provides thought leadership, community building, public policy, professional/workforce development and engaging events to bring forward the voice of its members. HIMSS encompasses more than 70,000 global individual members, 630 corporate members, and over 450 non-profit organizations. Thousands of volunteers work through HIMSS to leverage the innovation of digital health to improve both the health of individuals and populations, as well as the quality, cost-effectiveness and access of healthcare. For more information, visit https://www.himss.org/.

© 2018 NantHealth, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181107005800/en/

CONTACT

Media Contact:
NANT
Jen Hodson
Jen@NANT.com
562-397-3639

同じカテゴリーの記事 

  • joimax® Obtains Registration for All Products in the Indian Market
  • Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment for a Rare Brain Glioma Subtype in China
  • Inocras Pioneers Precision Health with Revolutionary Whole Genome Insights
  • エクセルゲン、バクスター・インターナショナルを提訴。口腔体温計の精度に関するデータの公表権を擁護
  • パース・バイオサイエンシズが研究室用自動化プロバイダー・プログラムをローンチし、ハミルトン、オープントロンズ、ラボワークス、SPTラボテックと提携